Related Experiment Video
Updated: Jun 16, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 9, 2014
IKK{beta} as a target for treatment of inflammation induced bone loss
1Laboratory of Gene Regulation and Signal Transduction, School of Medicine, University of California at San Diego, La Jolla, CA, USA.
Abstract:
The transcription factor nuclear factor (NF)-kappaB is well recognised as a pivotal player in osteoclastogenesis and inflammation induced bone loss. Here, the authors discuss their recent results, obtained using a genetic approach in mice, that indicate the importance of IKKbeta, and not IKKalpha, as a transducer of signals from receptor activator of NF-kappaB (RANK) to NF-kappaB. Ablation of IKKbeta results in lack of osteoclastogenesis and unresponsiveness of IKKbeta deficient mice to inflammation induced bone loss. In the need of a more effective therapy for the treatment of inflammatory diseases causing bone resorption, specific inhibition of IKKbeta represents a logical alternative strategy to the current therapies.
Insights
Nuclear factor-kappaB (NF-κB) drives bone loss. IκB kinase beta (IKKβ) is crucial for NF-κB signaling in osteoclastogenesis, unlike IKKα. Inhibiting IKKβ offers a potential therapy for inflammatory bone resorption.
Area of Science:
- Immunology
- Molecular Biology
- Bone Biology
Background:
- Nuclear factor-kappaB (NF-κB) is a key regulator of osteoclastogenesis and bone loss associated with inflammation.
- Receptor activator of NF-κB (RANK) signaling is critical for osteoclast differentiation and function.
Purpose of the Study:
- To investigate the specific role of IKKα and IKKβ in RANK-mediated NF-κB activation and osteoclastogenesis.
- To evaluate the therapeutic potential of targeting IKKβ in inflammatory bone loss.
Main Methods:
- Utilized a genetic approach in mice with targeted ablation of IKKα or IKKβ.
- Assessed osteoclastogenesis and bone loss in response to inflammatory stimuli.
Main Results:
- Ablation of IKKβ, but not IKKα, completely abolished osteoclastogenesis.
- IKKβ-deficient mice were unresponsive to inflammation-induced bone loss.
- IKKβ was identified as the critical transducer of RANK signals to NF-κB.
Conclusions:
- IKKβ is essential for RANK-induced NF-κB activation and osteoclastogenesis.
- Targeting IKKβ is a promising therapeutic strategy for inflammatory bone resorption and related diseases.
Related Concept Videos
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids